

50 Vantage (Class B EUR Accumulation Shares)

Undertakings for Collective Investment in Transferable Securities (UCITS)

May 2026

Month in Review

Equity markets rose in May. World equities rose 5.7% in euro terms. Japan was the strongest performer - followed by Emerging markets and Asia Pacific ex Japan. Europe and Small cap were the weakest performers. IT, Materials and Consumer discretionary were the strongest sectors. Energy, Utilities and Consumer staples were the weakest. Euro area bond markets rose by 1.1%.

Global growth was resilient but uneven in May. Eurozone inflation rose (3.2% YoY), fuelling expectations of possible ECB tightening, while the Fed remained cautious. Eurozone yields were volatile. Equities gained on strong earnings, led by AI-driven technology, with support from easing geopolitical tensions and lower oil prices.

iShares S&P 500 Information Technology Sector UCITS ETF, Schroder Asian Total Return Fund and Safran were the best performers. Otis Worldwide, Wolters Kluwer and CRH were the weakest performers. Within fixed income, BlueBay Investment Grade Euro Government Bond Fund was the best performer and Aegon European ABS Fund was the worst performer.

Historical Performance | Net of Fees

	1 MTH	3 MTH	YTD	1 YR	3 YR p.a	5 YR p.a
Vantage 50 Fund	4.0%	4.8%	5.7%	11.1%	9.2%	5.2%
Benchmark	3.4%	3.8%	6.9%	13.9%	11.4%	6.0%
	2025	2024	2023	2022	2021	Since Launch
Vantage 50 Fund	3.0%	12.9%	11.8%	-14.1%	14.3%	43.6%
Benchmark	4.7%	13.8%	12.5%	-14.9%	12.3%	64.2%

Source: Goodbody

The benchmark is a composite of 50% FTSE All World Index and 50% Bloomberg Barclays Euro Aggregate Bond Index

Regional Allocation as at 31 May 2026



- North America 44%
- Europe ex UK 42%
- UK 5%
- Asia Pacific 5%
- Emerging markets 4%

Source: Goodbody

Asset Allocation as at 31 May 2026



- Equity 53%
- Fixed Income 46%
- Cash 1%
- Property 0%
- Absolute fund 0%

Source: Goodbody

Fund Objective

The investment objective of the Fund is to deliver moderate real appreciation in the value of capital over the medium term. The Fund seeks to achieve this investment objective by investing primarily in a globally diversified portfolio of equity, fixed income assets, absolute strategies and cash instruments. The Fund will generally have a balanced investment between growth assets (i.e. equities) and income earning assets (fixed income and absolute strategies).

Key information

Fund launch date	28.08.2019
Fund type	UCITS
Base currency	€
Pricing/Dealing	Daily
ISIN	IE00BJR5X124
Month end NAV (€)	14.38
Investment management fee	1.00%

Summary Risk Indicator



Contact us today

Goodbody, 9-12 Dawson Street, Dublin 2
 T +353 1 641 9105
 T karl.s.goggin@goodbody.ie
 T www.goodbody.ie

Warning: If you invest in this fund you may lose some or all of the money you invest.

Warning: Past performance is not a reliable guide to future performance.

Warning: The value of your investment may go down as well as up.

Warning: This fund may be affected by changes in currency exchange rates.

Warning: Dividend Income is not guaranteed and may rise or fall in value.

The Fund is a sub-fund of Goodbody Funds ICAV, which is an undertaking for Collective Investment in Transferable Securities (UCITS) with limited liability between sub-funds. Investors should read the Prospective Supplement and Key Information document for the Fund, as well as the Information Memorandum prior to making a decision to invest, and for full information on the Fund including fees, risks and conflicts of interest.

This document is a marketing communication. This document is not in itself a prospectus, an invitation to invest or advice. Please refer to the UCITS prospectus and KID before making any final investment decisions.



www.goodbody.ie

Dublin 9-12 Dawson Street, Dublin 2, D02 YX99, Ireland T +353 1 667 0400	London 13th Floor, 70 St. Mary Axe, London, EC3A 8BE, UK T +44 203 841 6220	Cork City Quarter, Lapps Quay, Cork, T12 F70A, Ireland T +353 21 427 9266	Galway 18 Eyre Square, Galway, H91 TWE0, Ireland T +353 91 569 744	Wealth Management Investment Banking Asset Management Capital Partners
--	---	---	--	---

Prepared by Goodbody Investment Team

Produced May 2026

Disclaimer

This publication has been approved by Goodbody Stockbrokers UC. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

This document is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this publication constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. Goodbody Stockbrokers UC does not advise on the tax consequences of investments and you are advised to contact an independent tax advisor. Please note in particular that the basis and levels of taxation may change without notice. Private customers having access to this document, should not act upon it in anyway but should consult with their independent professional advisors. The price, value and income of certain investments may rise or may be subject to sudden and large falls in value. You may not recover the total amount originally invested.

Past performance should not be taken as an indication or guarantee of future performance; neither should simulated performance. The value of securities may be subject to exchange rate fluctuations that may have a positive or adverse effect on the price or income of such securities. Goodbody Stockbrokers UC and its associated companies and/or its officers may from time to time perform banking or Corporate Finance services including underwriting, managing or advising on a public offering for, or solicit business from any company recommended in this document. They may own or have positions in any securities mentioned herein and may from time to time deal in such securities.

Goodbody Stockbrokers UC is a registered market maker in the majority of companies listed on the Irish Stock Exchange plc, trading as Euronext Dublin. Protection of investors under the UK Financial Services and Markets Act 2000 (as amended) may not apply. Irish Investor Compensation arrangements will apply. For US Persons Only: This publication is only intended for use in the United States by Major Institutional Investors. A Major Institutional Investor is defined under Rule 15a-6 of the Securities Exchange Act 1934 as amended and interpreted by the SEC from time-to-time as having total assets in its own account or under management in excess of \$100 million.

All material presented in this publication, unless specifically indicated otherwise is copyright to Goodbody Stockbrokers UC. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Goodbody Stockbrokers UC.

Registered Office: 9-12 Dawson Street, Dublin 2, Ireland. T: +353 1 667 0400. Registered in Ireland No. 54223.

Goodbody Stockbrokers UC acts as broker to: AIB Group, Cairn Homes, CRH, Datalex, FD Technologies, Grafton Group, Greencore, Hostelworld Group, ICG, Kingspan, LungLife AI, Molten Ventures, Origin Enterprises, Playtech, Rank Group and Ryanair.

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland and Goodbody Stockbrokers UC is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a wholly owned subsidiary of Allied Irish Banks, p.l.c. Goodbody Securities Inc. is regulated by the SEC and a member firm of FINRA and SIPC. 001477_0925